Spire Drug Interactions

There is an increased risk of hyperkalemia if spironolactone is given with potassium supplements or with other potassium-sparing diuretics. Hyperkalemia may occur as well in patients also given ACE inhibitors, angiotensin II receptor antagonists NSAIDs, ciclosporin, or trilostane. In patients given spironolactone with NSAIDs or ciclosporin the risk of nephrotoxicity may also be increased. Diuretics may reduce the excretion of lithium and increase the risk of lithium toxicity.
Hyponatremia may occur in patients taking a potassium-sparing diuretic with a thiazide; this risk may be increased in patients given chlorpropamide. Spironolactone may reduce the ulcer-healing properties of carbenoxolone. As with other diuretics, spironolactone may enhance the effects of other antihypertensive drugs and may reduce vascular responses to noradrenaline.